Core Insights - Kestra Medical Technologies, Ltd. reported strong financial results for Q4 and FY25, driven by increased demand for its ASSURE® cardiac recovery system [3][5][6] - The company achieved a total revenue of $59.8 million in FY25, marking a 115% increase compared to FY24 [5][6] - Gross margin improved significantly, reaching 44.3% in Q4 FY25 and 40.5% for FY25, compared to 13.9% and 1.3% in the prior periods respectively [6][15] Financial Performance - Q4 FY25 revenue was $17.2 million, a 71% increase year-over-year, with 3,903 prescriptions written for the ASSURE® system, up 43% from the previous year [6][7] - The company generated a gross profit of $7.6 million in Q4 FY25, compared to $1.4 million in the same period last year [7][20] - GAAP net loss for Q4 FY25 was $51.1 million, compared to a loss of $22.3 million in Q4 FY24 [7][21] Operational Highlights - The company wrote a total of 13,193 prescriptions for the ASSURE® system in FY25, a 72% increase from FY24 [15] - Operating expenses for FY25 were $130.6 million, up from $85.4 million in FY24, largely due to increased commercial and revenue cycle resources [15][21] - Cash and cash equivalents stood at $237.6 million as of April 30, 2025, a significant increase from $8.2 million a year earlier [18] Future Outlook - Kestra has initiated revenue guidance for FY26 at $85 million, representing a 42% increase compared to FY25 [6][9] - The company remains focused on innovation and enhancing prescriber and patient support to drive market expansion [3][6]

Company Overview - Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through innovative monitoring and therapeutic intervention technologies [3]. Leadership Appointment - Conor Hanley has been appointed as an independent director to the board of Kestra Medical Technologies, effective June 4, 2025 [1]. - Brian Webster, President and CEO of Kestra, expressed enthusiasm about Hanley's appointment, highlighting his deep expertise in medical technology and cardiac care as a strategic resource for the company [2]. Conor Hanley's Background - Mr. Hanley is currently the CEO of FIRE1, a venture-backed company focused on connected medical device solutions for heart failure [2]. - He has held senior management roles at ResMed, leading the cardiology business unit and chronic disease management solutions globally [2]. - Hanley co-founded and served as CEO of BiancaMed, a medical device company acquired by ResMed, and holds a PhD in chemical engineering and an MBA [2]. Strategic Focus - Mr. Hanley expressed his honor in joining the Kestra board and emphasized the company's role in driving innovation in the wearable cardioverter defibrillator market [3]. - The company aims to scale its operations and fulfill its commitments to patients and prescribers [3].